Good
Partially Aligned
Patient Risk:
Low
Summary
Claims about Canadian availability and Canadian prescribing details are not addressed in the provided FDA label excerpts; only the indication component (insomnia with sleep onset and/or maintenance difficulties in adults) is directly supported.
Category Scores
Accurate Statements
In Canada, lemborexant is prescribed for insomnia that includes difficulty falling asleep and/or difficulty staying asleep.
INDICATIONS AND USAGE: indicated for treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Unsupported Statements
Lemborexant (Brand name: Dayvigo) is available in Canada.
The provided FDA label excerpts do not address country-specific market availability.
Lemborexant (Dayvigo) is used in Canada for the treatment of insomnia in adults.
The provided FDA label excerpts do not describe Canadian usage/authorization; they only provide FDA labeling information.
Contradictions
Important Omissions
No omissions related to safety, dosing, contraindications, warnings, interactions, or adverse reactions are assessed because the AI claims provided do not include such details.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The only label-relevant supported claim concerns the general indication description; the unsupported claims concern Canada availability/usage and do not themselves provide dosing or safety instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Country-specific statements (Canadian availability and prescribing) are unsupported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to the FDA-labeled indication wording provided (adult insomnia with difficulty sleep onset and/or sleep maintenance) and avoid asserting Canada-specific availability or prescribing unless supported by provided label/country documentation.